LivaNova Stock
LivaNova PLC
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United Kingdom
- CEO
- Vladimir A. Makatsaria
- Employees
- 3,300
- Market cap
- $4.3 B
- IPO
- 19/10/2015
LivaNova PLC (LIVN) operates in the healthcare/medical devices sector and is headquartered in the United Kingdom. The offering comprises specialized therapeutic solutions across three segments, including Cardiopulmonary for heart-lung procedures, Neuromodulation for the treatment of conditions such as epilepsy, and…
AI-generated company profile based on the figures on this page, last updated on 04/08/2026. Not investment advice.
LivaNova stock: price history
1D
-1.2%
1W
+1.6%
1M
-1.2%
6M
+15.6%
YTD
+26.1%
1Y
+44.0%
2Y
+45.9%
5Y
-7.5%
10Y
+36.4%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~71% stronger price swings than usual
LivaNova stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
LivaNova PLC is a globally operating medical technology company that develops and distributes specialized therapeutic solutions for cardiopulmonology, neuromodulation, and circulatory support. Its portfolio includes oxygenators, heart-lung machines, and implantable systems such as the VNS Therapy System for treating epilepsy and depression. The company distributes its products worldwide to hospitals and medical professionals through both its own sales teams and distributors. Beyond its core business, the company conducts research collaborations, including investigations into clinical biomarkers.
- Revenue model
- Hardware sales
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Low
Ask the agents about LivaNova
Analyst assessment of LivaNova
PRICE TARGET LOW
US$85.00
CONSENSUS
US$93.33
MEDIAN
US$92.50
PRICE TARGET HIGH
US$105.00
0
STRONG BUY
11
BUY
3
HOLD
1
SELL
0
STRONG SELL
15
TOTAL · Buy
As of: 02/09/2026
LivaNova stock metrics
P/E
22.49
P/B
3.22
EV/EBITDA
18.92
RETURN ON EQUITY
8.2%
NET MARGIN
27.8%
DEBT/EQUITY
0.27
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.8%
FLOAT SHARES
54,836,771
AVG. DAILY VOLUME (30D)
642,286
Insider transactions (SEC)
Bianchi Francesco
Story Brooke
Bianchi Francesco
Tezel Ahmet
Tezel Ahmet
Attention
Price since yesterday: -1.2%
Search (Google Trends)
Institutional holders
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about LivaNova stock
What does LivaNova do?
LivaNova PLC is a company in the Healthcare sector, Medical - Devices industry, headquartered in United Kingdom.
The CEO is Vladimir A. Makatsaria, the company employs around 3,300 people.
The IPO was on 19/10/2015; the stock trades on NASDAQ under the ticker LIVN.
What do analysts say about LivaNova stock?
15 analysts rate the stock, the consensus is Buy (as of 02/09/2026).
The average price target is US$93.33, ranging from US$85.00 to US$105.00, with a median of US$92.50.
This is an external assessment, not a statement by Market Jury.
When does LivaNova report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 71% stronger than usual.
Does LivaNova pay a dividend?
No, LivaNova currently does not pay a dividend.
Which stocks are comparable to LivaNova?
Comparable stocks include Smith & Nephew, Abbott Laboratories, Medtronic, Stryker, Boston Scientific, Edwards Lifesciences, Siemens Healthineers and DexCom.
How can I get LivaNova stock analyzed?
Clicking "Analyze stock" lets five strategies assess LivaNova against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.